Related Experiment Videos
Pharmacokinetics of theophylline in neonates
Insights
Theophylline effectively treats apnea of prematurity in neonates. Dosing requires careful monitoring due to unique infant metabolism and potential toxicity, necessitating individualized treatment plans.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Pediatrics
Background:
- Apnea of prematurity is a common concern in neonates.
- Theophylline is a recognized treatment for this condition.
- Understanding theophylline's behavior in preterm infants is crucial.
Purpose of the Study:
- To review the pharmacokinetics and metabolism of theophylline in preterm neonates.
- To establish appropriate dosing guidelines for theophylline in this population.
- To highlight the importance of individualized therapy and toxicity monitoring.
Main Methods:
- Extensive review of pharmacokinetic studies in preterm neonates.
- Analysis of theophylline metabolism, including methylation to caffeine.
- Comparison of neonatal pharmacokinetics with those in children and adults.
Main Results:
- Preterm neonates exhibit prolonged half-life and low clearance of theophylline.
- Larger volume of distribution and decreased protein binding are observed.
- Lower maintenance dose requirements compared to older children are noted.
Conclusions:
- Theophylline is a safe and effective treatment for apnea of prematurity.
- Initial dosing guidance: 5 mg/kg loading dose, followed by 2 mg/kg every 12 hours maintenance.
- Individualized dosing based on serum levels and apnea monitoring is essential to prevent toxicity.
Abstract:
Theophylline is a safe, effective drug for the treatment of apnea of prematurity. The pharmacokinetics of theophylline have been studied extensively in preterm neonates. There is some inter-infant variability, but generally, compared to children and adults, prolonged half-life values and low clearance rates have been found: the apparent volume of distribution is larger and protein binding of the drug is decreased. A unique pattern of metabolism involving methylation to caffeine has been identified. Theophylline maintenance dose requirements are much lower in neonates than in children. When therapy is begun, a useful guide is to give a loading dose of 5 mg/kg anhydrous theophylline followed by maintenance doses of 2 mg/kg every 12 hr. In many infants, this will suffice to prevent apnea without producing signs of toxicity. After commencement of therapy, doses must be individualized for each infant on the basis of serum theophylline concentration monitoring and monitoring for apnea. Evidence of theophylline toxicity in neonates may be subtle, and only scanty data are available regarding possible long-term effects of chronic theophylline treatment of neonates.